Qiagen N.v. · NYSE:QGEN
Qiagen — Wolfe Research Healthcare Conference 2025
56 slides from Qiagen's conference presentation, November 2025
Slide 1: Committed to solid profitable growth
Committed to solid profitable growth Investor Introduction November 2025 Presentation Titel
Slide 2: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amend
Slide 3: The value of biology has never been stronger
The value of biology has never been stronger Crucial to Improving Direct impact advancing healthcare on your science for all lives Investor Introduction Presentation Titel 3
Slide 4: QIAGEN solutions are used worldwide
QIAGEN solutions are used worldwide by researchers - from young scientists to Nobel laureates - and clinical labs Investor Introduction Presentation Titel 4
Slide 5: QIAGEN more focused and stronger than ever
QIAGEN more focused and Growth and value stronger than ever ~4-6% CAGR ~$13-14 bn ~$11 bn addressable Life Molecular addressable market QIAGEN market (2028) Sciences Diagnostics customers (2024) ~50% ~50% QIAGEN product Sample technologies Balanced global presence 2024 net sales (%) groups 52 33 15
Slide 6: Leading from the first step in lab workflows
Leading from the first step in lab workflows Samples Sample preparation Detection Insights PCR QIAcuity dPCR #2 Any Genomics / NGS Sample #1 biological technologies QIAGEN Digital Insights #1 sample Diagnostic solutions QuantiFERON #1 QIAstat-Dx #3 Life Sciences Customers Molecular Diagnostics Custo
Slide 7: Strategy: Committed to solid profitable growth
Strategy: Committed to solid profitable growth Our 2028 targets Sharpen focus on growth pillars to At least $2 bn sustain profitable growth net sales CER from pillars in 2028 ~7% At least 250 bps Net sales CER CAGR Drive efficiency and digitization to fuel (2024-28) growth investments and profitabil
Slide 8: Focusing on attractive opportunities in molecular testing
Focusing on attractive opportunities in molecular testing Product PCR / Nucleic acid Sample technologies Diagnostic solutions NGS / Genomics groups amplification 2024 sales $642 mn $749 mn $300 mn $234 mn Accelerate investments for growth Build on proven leadership QIAcuity #2 QIAstat-Dx #3 QIAGEN #
Slide 9: QIAcuity dPCR
QIAcuity dPCR Quantitative PCR QIAcuity dPCR Next-generation (qPCR) Enabling novel applications sequencing (NGS) e.g., Cell and Gene Therapy e.g., liquid biopsy Lower sensitivity High sensitivity and precision In-depth insights and precision More accurate than qPCR and high precision dPCR – Capturin
Slide 10: Instruments tailored to varying customer segments
Instruments tailored to varying customer segments Key achievements Scalable systems Low- to high- throughput capabilities QIAcuity One QIAcuity Four QIAcuity Eight QIAcuity-Dx >2,700 cumulative placements Academia since 2020 launch Overcoming entry barrier vs. qPCR Ease of use Fully integrated Trans
Slide 11: Significant investments into QIAcuity dPCR
Significant investments into QIAcuity dPCR ≥$250 mn QIAcuity net sales CER target (2028) Target Extend Accelerate commercialization new applications into clinical use >3x increase Add >100 assays QIAcuity-Dx of sales specialists for market menu expansion for CGT and enabling MRD and monitoring penet
Slide 12: QIAstat-Dx
QIAstat-Dx Use case: 3-year-old with severe but unspecific GI symptoms Traditional testing Syndromic testing Slow diagnosis and treatment Fast diagnosis enabling better decisions can lead to complexities treatment decisions Identifying unknown diseases at speed Day 1 Day 1 One test within and ease o
Slide 13: QIAstat-Dx offers differentiated features
QIAstat-Dx offers differentiated features Key achievements Strong product capabilities Key differentiators Specification QIAstat-Dx Competition Workflow Additional >4,600 cumulative placements efficiency pathogens since launch Hands-on time ~1 min >5 min and safety on panels for for broader robust r
Slide 14: Expanding global presence and differentiated menu
Expanding global presence and differentiated menu ≥$200 mn QIAstat-Dx net sales CER target (2028) Grow installed Small hospitals Medium hospitals Large hospital networks customer Public health labs Regional reference labs National reference labs base Low-throughput High-throughput customers customer
Slide 15: QIAGEN Digital Insights
QIAGEN Digital QIAGEN unlocking the power of genomics Insights Development Genomic data In 2003, the first Today, any human human genome took genome can be read in 13 years 5 hours Sequencing Powerful analytics costs $100 / to understand >$1 bn / genome sequencing run 2000 2010 2020 2030 genomics Th
Slide 16: Top bioinformatics for research to clinical customers
Top bioinformatics for research to clinical customers Key achievements Addressing large customer base Delivering QDI software solutions for NGS workflow #1 Research – in bioinformatics software for research and clinical Scientific discovery Pharma / Biotech Academia Government research Sample prep L
Slide 17: Case study: Research Advancing drug development
Case study: Research Advancing drug development Pharma challenge QDI pivotal to drug discovery Over 50,000 scientific publications cite our software Key to understanding disease pathways, targets and measure changes 24 of the Top 25 Pharma companies use QDI Significant number of failures without the
Slide 18: Case study: Clinical Enhancing patient outcomes
Case study: Clinical Enhancing patient outcomes Patient situation QDI-enhanced patient outcome Mutation identification and recommendation by QDI Profile Male (early 70s) Targeted therapy leading to life-saving disease remission Diagnosis QIAGEN Clinical Leukemia linked to rare gene mutation Insights
Slide 19: Focus on SaaS subscription model and AI
Focus on "SaaS" subscription model and AI to expand market leadership 2028 goals Coming in 2025 Deepen global commercial reach and +40% 3 new AI product SaaS sales SaaS transition for sustainable growth specialists enhancements >14 10+ new DATA Invest in new AI technologies AI-enabled applications S
Slide 20: Investing to extend market leadership
Investing to extend market leadership ≥$200 mn QDI net sales CER target (2028) Extend leadership in curated Deepen global Invest in new AI and other knowledge commercial reach technologies Expand QIAGEN knowledge base into Adopt SaaS go-to-market Continue advancing software spatial, proteomics and m
Slide 21: Sample technologies
Sample technologies Laboratory workflow Differentiated solutions for PCR Valuable Biological Sample modular, integrated workflows molecular sample technologies insights Fast time to result, scalability Critical step in and ease of use dPCR High-quality molecular sample prep key to workflows Platform
Slide 22: Leader in the first step of lab workflows
Leader in the first step of lab workflows Key achievements Comprehensive Any >350 DNA / RNA consumables portfolio biological sample different sample kits target analytes >120 mn QIAGEN preparations e.g., tissue, cells, blood, for manual and sold per year including variations serum, wastewater automa
Slide 23: On the offense expanding our top automation portfolio
On the offense expanding our top automation portfolio Low-throughput Mid-throughput High-throughput ≥$750 mn Sample technologies net sales CER target (2028) QIAmini QIAsymphony QIAsprint Connect Connect Launch 2026 Launch 2025 Launch 2026 Addition to QIAcube / EZ Flagship system upgrade, Market Entr
Slide 24: QuantiFERON Tuberculosis: A highly contagious and lethal infection
QuantiFERON Tuberculosis: A highly contagious and lethal bacterial infection 1 in 4 Broad health risk Global relevance people have a latent TB bacterial infection High risk of ssion to active ogre TB pr 1 in 10 EMEA of these people will develop an Immunocompromised ~10 mn active TB bacterial infecti
Slide 25: Best-positioned test for latent TB detection
Best-positioned test for latent TB detection QuantiFERON Tuberculin Key achievements Advantages over Specification blood test skin test skin test Customizable automated workflow High accuracy and specificity $454 mn 2024 net sales (+89% vs. 2019) Only one patient visit Electronic results Quality-ass
Slide 26: Driving skin test conversion with unrivaled automation
Driving skin test conversion with unrivaled automation ≥$600 mn QuantiFERON Leading automation advantage net sales CER target (2028) Automated Automated Increase liquid handling assay and result Partnership with customer base Diasorin to expand into Lyme disease (EU and U.S.) Large potential in skin
Slide 27: Initiatives to fuel growth investments
Initiatives to fuel growth investments and achieve ≥31% adjusted operating income margin in 2028 Operational excellence Digitization Positioning QIAGEN for stronger profitable growth Accelerating growth and efficiency across QIAGEN Organizational design Portfolio streamlining >6 million ~30 website
Slide 28: Executing our strategy with empowered QIAGENers
Executing our strategy with empowered QIAGENers Great Great Great Great Great Great ~5,700 Place Place Place Place Place Place To To To To To To Work ® Work ® Work ® Work ® Work ® Work ® Certified Certificada Certificada Certified Certified Certified NOV 2023–NOV 2024 DEC 2022–DEC 2023 OCT 2023–OCT
Slide 29: Embracing ESG for all stakeholders
Embracing ESG for all stakeholders Net zero Top ESG ratings Environmental responsibility carbon emission target (2050) Investing in people 37% female leadership (2024) Serving society >50 public health partnerships (2024) Business with integrity ~8,000 compliance trainings completed (2024) Investor
Slide 30: Q3 2025 results
Q3 2025 results Delivering results above outlook November 4, 2025
Slide 31: Forward looking and intended use statements
Forward looking and intended use statements Safe Harbor Statement: Certain statements in this presentation may constitute forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amend
Slide 32: Q3 2025: Delivering results above outlook
Q3 2025: Delivering results above outlook Growth Continued solid momentum across the portfolio $533 mn ($525 mn CER) • Core sales +6% CER to $532 mn ahead of outlook for ≥5%; net sales +5% CER Net sales • QIAstat-Dx (+11% CER) and QuantiFERON (+11% CER) lead growth, while Sample technologies +5% CER
Slide 33: Q3 2025: Sales performance and key developments
Q3 2025: Sales performance and key developments Sales by product group Key developments (In $ millions at actual rates) • +3% CER growth driven by automated consumables +5% Sample • Instrument placements led by QIAcube, QIAsymphony and CER(1) technologies EZ2 systems 533 502 • +11% CER growth suppor
Slide 34: Q3 2025: Portfolio developments
Q3 2025: Portfolio developments Sample technologies: QIAstat-Dx: Genomics / NGS: Advancing automated sample processing Expanding syndromic testing access Advancing NGS solutions Expanding global installed base of High-throughput system expands U.S. Launch of new QIAseq xHYB long read QIAcube Connect
Slide 35: Disciplined capital allocation
Disciplined capital allocation: Targeted actions to drive growth and enhance shareholder return Organic Profitable targeted investments Acquisition of investments into growth pillars and digitization to fuel profitable Parse Biosciences business expansion Expanding Sample technologies into high-grow
Slide 36: Parse Biosciences acquired by QIAGEN
Parse Biosciences, the fastest-growing single-cell company, acquired by QIAGEN Key Facts 3,000+ labs globally Number of labs adopting Parse Founded: 2018 3000 HQ in Seattle (U.S.) FTE: ~100 40+ countries Revenue: 2000 ~$22 mn (2024) ~$40 mn (2026 estimate) Acquired data analysis 50 of the top 50 100
Slide 37: The future of high-definition biology is single-cell resolution
The future of high-definition biology is single-cell resolution Single-cell market Opportunity for QIAGEN ~10% CAGR The future standard method for discovery Expanding QIAGEN's Sample tech Shifting to single-cell across all translational portfolio into the scalable fast-growing ~$2.1 bn single-cell m
Slide 38: Q3 2025: Ongoing solid profitability improvements
Q3 2025: Ongoing solid profitability improvements Adj. operating income margin Adj. EPS ahead of Q3 2025 outlook 29.6% 29.6% Adj. +6% to $158 million despite tariffs 30.0% CER operating and currency headwinds income Non- 18% adj. tax rate consistent with operating quarterly estimate income $0.61 Adj
Slide 39: 9M 2025: Continuous high cash flow
9M 2025: Continuous high cash flow Cash flow(1) Debt maturity overview (3) 770 (in $ millions) 20 In $ millions Q3 2025 Q3 2024 Change 624 Operating cash flow 165 182 -10% Purchases of PP&E(2) -46 -43 +5% 124 500 Free cash flow 119 139 -14% Likely repayment in 2025(4) 750 500 164 In $ millions 9M 20
Slide 40: Outlook: Q4 and FY 2025
Outlook: Q4 and FY 2025 As of October 31, 2025 Outlook Q4 2025 FY 2025 Net sales ~+0% CER / +4-5% CER(2) / ~+2% CER core portfolio(1) +5-6% CER core portfolio(1,3) Anticipated currency impact Positive impact of ~+1 ppt Positive impact of ~+1 ppt Adjusted diluted EPS ~$0.60 CER ~$2.38 CER (previously
Slide 41: On track to achieve 2025 targets
On track to achieve 2025 targets Delivering solid financial performance Net sales and adjusted EPS exceeded outlook Driving growth through portfolio expansion Building momentum across growth pillars, led by Sample technologies with three new automation launches and the Parse Biosciences acquisition
Slide 42: Welcoming the new Head of Investor Relations
Welcoming the new Head of Investor Relations Daniel Wendorff Appointed Vice President, Head of Investor Relations, effective November 1, 2025 • Will lead QIAGEN's global investor engagement, reporting to Roland Sackers (CFO) • Deep industry experience and capital markets expertise • Joins from Merck
Slide 43: Appendix
QIAGEN Appendix
Slide 44: Q4 and FY 2025: Outlook and assumptions
Q4 and FY 2025: Outlook and assumptions (As of October 31, 2025) Q4 2025 outlook FY 2025 outlook Net sales ~+0% CER / ~+2% CER core portfolio(1) +4-5% CER / +5-6% CER core portfolio(1) Anticipated currency impact(2) Positive impact of ~+1 ppt Positive impact of ~+1 ppt ~$0.60 CER ~$2.38 CER Adjusted
Slide 45: Q3 2025: Consolidated Statements of Income
Q3 2025: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Three months ended Three months ended September 30, 2025 September 30, 2024 Net sales 532,583 501,869 Cost of sales: Cost of sales 187,783 179,817 Acquisition-related intangible amortization 13,541 13,745 Tota
Slide 46: 9M 2025: Consolidated Statements of Income
9M 2025: Consolidated Statements of Income (unaudited) (In $ thousands, except share data) Nine months ended Nine months ended September 30, 2025 September 30, 2024 Net sales 1,549,579 1,457,012 Cost of sales: Cost of sales 535,028 777,922 Acquisition-related intangible amortization 40,325 45,030 To
Slide 47: 2025: Quarterly sales by product group
2025: Quarterly sales by product group Q1 2025 Q2 2025 Q3 2025 Q4 2025 YTD 2025 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sample technologies 150 -3% -1% 166 2% 0% 170 5% 3% 486 1% 1% Diagnostic solutions(
Slide 48: 2025: Quarterly sales by product type and region
2025: Quarterly sales by product type and region Q1 2025 Q2 2025 Q3 2025 Q4 2025 YTD 2025 (In $ millions at actual rates / change in actual, CER rates) Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Sales Act. CER Product type Consumables and related 435 6% 8% 476 8% 6% 481 7% 6% 1,393
Slide 49: Q3 and 9M 2025: Reconciliation to adjusted results
Q3 and 9M 2025: Reconciliation to adjusted results (unaudited) (In $ millions, except EPS) Net Gross Operating Pre-tax Income Tax Net Diluted sales profit income income tax rate income EPS* Third quarter 2025 Reported results 532.6 331.2 129.2 134.8 (4.7) 3 % 130.1 0.60 Adjustments Business integrat
Slide 50: Q3 and 9M 2025: Footnotes for reconciliation
Q3 and 9M 2025: Footnotes for reconciliation to adjusted results (unaudited) a. Results include costs for acquisition projects, including the acquisition of GNX Data Systems Ltd. (doing business as Genoox) completed in May 2025. It also includes costs incurred in connection with streamlining operati
Slide 51: 2025: Quarterly income statement summary
2025: Quarterly income statement summary (In $ millions, unless indicated) (Diluted EPS in $ per share) Q1 2025 Q2 2025 Q3 2025 Q4 2025 FY 2025 Net sales 483.5 533.5 532.6 1,549.6 Net sales (CER) 491.2 491.2 524.8 1,541.7 Gross profit 308.7 334.3 331.2 974.2 Gross profit margin 63.8% 62.7% 62.2% 62.
Slide 52: Consolidated Balance Sheets
Consolidated Balance Sheets (unaudited) September 30, December 31, September 30, December 31, (In $ thousands, except par value) 2025 2024 (In $ thousands, except par value) 2025 2024 (revised) (revised) Assets Liabilities and Equity Cash and cash equivalents 1,355,594 663,555 Current portion of lon
Slide 53: Consolidated Statements of Cash Flows
Consolidated Statements of Cash Flows (unaudited) Nine months ended September 30, September 30, Nine months ended September 30, September 30, (In $ thousands) 2025 2024 (In $ thousands) 2025 2024 Cash flows from operating activities: Cash flows from financing activities: Net income (loss) 317,051 (4
Slide 54: Q3 and 9M 2025: Currency impact
Q3 and 9M 2025: Currency impact Net sales Net sales Currency exposure Change (In $ millions / Actual) (CER) (As % of CER sales) (In $ millions) Q3 2025 U.S. dollar 301.8 301.8 57% 0.0 Euro 100.1 94.2 18% -5.9 British pound 22.6 21.8 4% -0.8 Japanese yen 9.7 9.6 2% -0.1 Other currencies 98.4 97.4 19%
Slide 55: Employees as of September 30, 2025
Employees as of September 30, 2025 Europe / Middle Asia Pacific / Total Total Americas East / Africa Japan / ROW Q3 2025 Q2 2025 Change Production 279 1,106 145 1,530 1,570 -3 % R&D 163 774 55 992 993 0% Sales 563 845 718 2,126 2,104 1% Marketing 73 173 73 319 319 0% Administration 77 455 161 693 67
Slide 56: Your contacts
Your contacts Daniel Wendorff Calendar Vice President E-mail: Head of Investor Relations Sample technologies Deep Dive November 21, 2025 ir@qiagen.com Phone: +49 2103 29 11322 Internet: E-mail: daniel.wendorff@qiagen.com Q4 / FY 2025 results February 2026 corporate.QIAGEN.com Dr. Domenica Martorana